MAFTEST analyses of the NSABP-B34 and AZURE landmark clinical trials confirmed clinical utility of the MAFTEST for selection of early-stage breast cancer patients that benefit from adjuvant
/PRNewswire/ Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III).
The Royal Mail share price has taken a beating in 2022, leading to the company's demotion from the FTSE 100. Our writer considers where it could go next.
Peel Hunt has recommended investors sell rather than buy shares in the postal service giant and has slashed its target price for the group from 500p per share to 307p.
Turbulent times are continuing for the airline industry and there are dark clouds ahead that could extend for some time yet. Bad news came in triplicate for.